Blog
RSS FeedPosted by Michael Wonder on 07 May 2021
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy
7 May 2021 - NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or ...
Posted by Michael Wonder on 06 May 2021
Preliminary NICE 'no' for Merck's Bavencio
6 May 2021 - NICE has issued a preliminary rejection of NHS funds for use of Merck Serono's Bavencio (avelumab) ...
Posted by Michael Wonder on 22 Apr 2021
Delcath Systems announces revised NICE guidance for Chemosat in the United Kingdom
21 April 2021 - Recommends special arrangement designation which increases reimbursement options. ...
Posted by Michael Wonder on 21 Apr 2021
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia
20 April 2021 - Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated ...
Posted by Michael Wonder on 20 Apr 2021
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer
20 April 2021 - NICE has today published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund for ...
Posted by Michael Wonder on 12 Apr 2021
Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision-making
12 April 2021 - This research aims to explore how often NICE uses immature overall survival data to inform reimbursement ...
Posted by Michael Wonder on 07 Apr 2021
Thousands to benefit from five minute breast cancer treatment
6 April 2021 - NHS England is rolling out an injection that dramatically cuts the amount of time breast cancer ...
Posted by Michael Wonder on 31 Mar 2021
NICE publishes guidance on new use for Kisqali
31 March 2021 - NICE has published an evidence base recommendation on ribociclib succinate (Kisqali) for the treatment of adults ...
Posted by Michael Wonder on 22 Mar 2021
Triple therapy recommended by NICE for patients with multiple myeloma
22 March 2021 - The therapy has been recommended after a confidential discount was agreed between NHS England and the drug ...
Posted by Michael Wonder on 19 Mar 2021
Ovarian cancer patients to have NICE approved drug combination option on Cancer Drugs Fund
19 March 2021 - A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary ...
Posted by Michael Wonder on 19 Mar 2021
NICE rejects Keytruda for advanced bladder cancer in final guidance
18 March 2021 - The UK’s NICE has issued a second final appraisal document rejecting MSD’s Keytruda for the treatment ...
Posted by Michael Wonder on 10 Mar 2021
NICE publishes updated guidance on the use of pembrolizumab (Keytruda) for patients with untreated, metastatic, non-squamous non-small-cell lung cancer
10 March 2021 - Pembrolizumab was listed in the Cancer Drugs Fund for this indication. ...
Posted by Michael Wonder on 09 Mar 2021
NICE rejects AZ’s Lynparza for metastatic prostate cancer
9 March 2021 - The UK’s NICE appraisal committee has chosen not to recommend AstraZeneca’s PARP inhibitor Lynparza for BRCA-positive ...
Posted by Michael Wonder on 04 Mar 2021
NICE rejects rare blood cancer treatment Poteligeo in final appraisal
4 March 2021 - The UK’s NICE has not recommended Kyowa Kirin’s Poteligeo for the treatment of adults living with ...
Posted by Michael Wonder on 26 Feb 2021
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
26 February 2021 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for ...